Martin J van den Bent

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p
    Martin J van den Bent
    Departments of Neurology and Pathology, Daniel den Hoed Cancer Center Erasmus University Hospital, Rotterdam, The Netherlands
    J Clin Oncol 24:2715-22. 2006
  2. ncbi request reprint Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays
    Pim J French
    Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
    Cancer Res 67:5635-42. 2007
  3. doi request reprint Interlaboratory comparison of IDH mutation detection
    Martin J van den Bent
    Department of Neurology Neuro Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam, The Netherlands
    J Neurooncol 112:173-8. 2013
  4. doi request reprint Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951
    Martin J van den Bent
    Neuro Oncology Unit, Erasmus MC Daniel den Hoed Cancer Center, PO Box 5201, 3008AE Rotterdam, The Netherlands
    J Clin Oncol 31:344-50. 2013
  5. ncbi request reprint Management of metastatic (parenchymal, leptomeningeal, and epidural) lesions
    M J van den Bent
    Neuro Oncology Unit, Daniel den Hoed Oncology Center, Erasmus University Hospital, Rotterdam, The Netherlands
    Curr Opin Oncol 16:309-13. 2004
  6. pmc Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective
    Martin J van den Bent
    Department of Neuro Oncology, Daniel den Hoed Oncology Center, 3008 AE Rotterdam, The Netherlands
    Acta Neuropathol 120:297-304. 2010
  7. ncbi request reprint Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971
    M J van den Bent
    Department of Neuro Oncology, University Hospital Rotterdam Rotterdam Cancer Center, The Netherlands
    J Clin Oncol 21:2525-8. 2003
  8. pmc MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951
    Martin J van den Bent
    Department of Neuro Oncology and Pathology, Daniel den Hoed Cancer Center and Erasmus University Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 27:5881-6. 2009
  9. ncbi request reprint The role of chemotherapy in brain metastases
    M J van den Bent
    Neurooncology Unit, Daniel den Hoed Cancer Center Erasmus University Medical Center, PO Box 5201, 3008AE Rotterdam, The Netherlands
    Eur J Cancer 39:2114-20. 2003
  10. ncbi request reprint European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme
    M J van den Bent
    Department of Neuro Oncology, Daniel den Hoed Cancer Center Erasmus University Medical Center, Rotterdam, The Netherlands
    Ann Oncol 14:1732-4. 2003

Detail Information

Publications93

  1. ncbi request reprint Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p
    Martin J van den Bent
    Departments of Neurology and Pathology, Daniel den Hoed Cancer Center Erasmus University Hospital, Rotterdam, The Netherlands
    J Clin Oncol 24:2715-22. 2006
    ....
  2. ncbi request reprint Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays
    Pim J French
    Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
    Cancer Res 67:5635-42. 2007
    ..The splice variants identified by exon level expression profiling may help to detect the genetic changes that cause or maintain gliomas and may serve as novel treatment targets...
  3. doi request reprint Interlaboratory comparison of IDH mutation detection
    Martin J van den Bent
    Department of Neurology Neuro Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075EA, Rotterdam, The Netherlands
    J Neurooncol 112:173-8. 2013
    ..IDH sequencing procedures yielded inconsistent results in 2 out of 6 laboratories. Quality assurance is pivotal before IDH testing is made part of clinical management of patients...
  4. doi request reprint Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951
    Martin J van den Bent
    Neuro Oncology Unit, Erasmus MC Daniel den Hoed Cancer Center, PO Box 5201, 3008AE Rotterdam, The Netherlands
    J Clin Oncol 31:344-50. 2013
    ..We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy (RT)...
  5. ncbi request reprint Management of metastatic (parenchymal, leptomeningeal, and epidural) lesions
    M J van den Bent
    Neuro Oncology Unit, Daniel den Hoed Oncology Center, Erasmus University Hospital, Rotterdam, The Netherlands
    Curr Opin Oncol 16:309-13. 2004
    ..For many patients, the overall prognosis is determined by the systemic disease status, but a subset of patients may benefit from more intensive treatment...
  6. pmc Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective
    Martin J van den Bent
    Department of Neuro Oncology, Daniel den Hoed Oncology Center, 3008 AE Rotterdam, The Netherlands
    Acta Neuropathol 120:297-304. 2010
    ..Routine pathology review in everyday clinical practice should be considered. More objective histological criteria for the grade and lineage of gliomas are urgently needed...
  7. ncbi request reprint Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971
    M J van den Bent
    Department of Neuro Oncology, University Hospital Rotterdam Rotterdam Cancer Center, The Netherlands
    J Clin Oncol 21:2525-8. 2003
    ..We investigated TMZ as first-line chemotherapy in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after surgery and radiation therapy...
  8. pmc MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951
    Martin J van den Bent
    Department of Neuro Oncology and Pathology, Daniel den Hoed Cancer Center and Erasmus University Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 27:5881-6. 2009
    ..It is unknown if MGMT promoter methylation is also predictive to outcome to RT followed by adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy in patients with anaplastic oligodendroglial tumors (AOT)...
  9. ncbi request reprint The role of chemotherapy in brain metastases
    M J van den Bent
    Neurooncology Unit, Daniel den Hoed Cancer Center Erasmus University Medical Center, PO Box 5201, 3008AE Rotterdam, The Netherlands
    Eur J Cancer 39:2114-20. 2003
    ..These anti-epileptic drugs should be avoided in patients requiring chemotherapy with agents metabolised through the cytochrome P450...
  10. ncbi request reprint European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme
    M J van den Bent
    Department of Neuro Oncology, Daniel den Hoed Cancer Center Erasmus University Medical Center, Rotterdam, The Netherlands
    Ann Oncol 14:1732-4. 2003
    ..We investigated this drug in a multicenter prospective phase II trial in recurrent glioblastoma multiforme (GBM)...
  11. ncbi request reprint Prevention of chemotherapy-induced neuropathy: leukemia inhibitory factor
    Martin J van den Bent
    Neuro Oncology Unit, Daniel den Hoed Oncology Center Erasmus University Medical Center, PO Box 5201, 3008 AE Rottterdam, Netherlands
    Clin Cancer Res 11:1691-3. 2005
  12. doi request reprint IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
    Martin J van den Bent
    Dept Neuro Oncology and Pathology, Daniel den Hoed Cancer Center and Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Clin Cancer Res 16:1597-604. 2010
    ....
  13. ncbi request reprint Advances in the biology and treatment of oligodendrogliomas
    M J van den Bent
    Neuro Oncology Unit, Daniel den Hoed Oncology Center Erasmus University Medical Center, 3008AE Rotterdam, The Netherlands
    Curr Opin Neurol 17:675-80. 2004
    ..This review discusses recent molecular, genetic and clinical advances made in studies on oligodendroglioma and mixed oligoastrocytoma...
  14. ncbi request reprint Current and future trials of the EORTC brain tumor group
    M J van den Bent
    Department of Neuro Oncology Neurology Daniel den Hoed Cancer Center Erasmus Medical Center, Rotterdam, The Netherlands
    Onkologie 27:246-50. 2004
    ..The wide recognition of the importance of translational research for clinical trials and in particular with targeted therapies implies that this type of research will become a mandatory element in many of our future trials...
  15. ncbi request reprint Surgical resection improves outcome in metastatic epidural spinal cord compression
    Martin J van den Bent
    Daniel den Hoed Oncology Center, Neuro Oncology Unit, 3008 AE Rotterdam, Netherlands
    Lancet 366:609-10. 2005
  16. ncbi request reprint Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial
    M J van den Bent
    Erasmus Medical Centrum Daniel den Hoed Oncology Center, Rotterdam
    Lancet 366:985-90. 2005
    ..In 1986 the EORTC Radiotherapy and Brain Tumor Groups initiated a prospective trial to compare early radiotherapy with delayed radiotherapy. An interim analysis has been reported. We now present the long-term results...
  17. ncbi request reprint Predictive and prognostic markers in neuro-oncology
    Martin J van den Bent
    Department of Neuro Oncology, Daniel den Hoed Cancer Center Erasmus University Medical Center, Rotterdam, The Netherlands
    J Neuropathol Exp Neurol 66:1074-81. 2007
    ..Last but not least there is the question of what added value the test has; this criterion determines the clinical usefulness of the assay and why some recently introduced molecular assays need to be scrutinized...
  18. ncbi request reprint Anaplastic oligodendroglioma and oligoastrocytoma
    Martin J van den Bent
    Neuro Oncology Unit, Daniel den Hoed Cancer Clinic Erasmus University Medical Center, PO Box 5201, 3008AE Rotterdam, The Netherlands
    Neurol Clin 25:1089-109, ix-x. 2007
    ..Observations have led to the current tendency to consider 1p/19q loss low-grade and anaplastic oligodendroglioma a separate biologic entity, at least within clinical trials, since they have a much better outcome...
  19. pmc Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
    Martin J van den Bent
    Neuro Oncology Unit, Daniel den Hoed Cancer Center, PO Box 5201, 3008AE Rotterdam, The Netherlands
    J Clin Oncol 27:1268-74. 2009
    ..In approximately 25% of instances, constitutively activated EGFR mutants are present. These observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM...
  20. ncbi request reprint [Issues around diffuse glioma]
    Martin J van den Bent
    Daniel den Hoed Oncologisch Centrum, Erasmus MC, Afd Neurologie Neuro oncologie, The Netherlands
    Ned Tijdschr Geneeskd 155:A3798. 2011
    ....
  21. doi request reprint Oligodendroglioma
    Martin J van den Bent
    Daniel den Hoed Cancer Clinic Erasmus University Medical Center, Rotterdam, The Netherlands
    Crit Rev Oncol Hematol 66:262-72. 2008
    ..Adjuvant PCV chemotherapy increased progression-free survival but does not improve survival as compared to PCV given at recurrence. Chemotherapy with either PCV or temozolomide constitutes a standard for recurrent/progressive disease...
  22. ncbi request reprint Recent developments in the use of chemotherapy in brain tumours
    Martin J van den Bent
    Department of Neuro Oncology, Daniel den Hoed Cancer Center Erasmus University Hospital Rotterdam, P O Box 5201, 3008AE Rotterdam, The Netherlands
    Eur J Cancer 42:582-8. 2006
    ..Trials exploring the role of chemotherapy in low-grade glioma are ongoing. No standard chemotherapy is currently available for highly anaplastic glioma failing first-line temozolomide-based therapy...
  23. ncbi request reprint Diagnosis and management of oligodendroglioma
    M J van den Bent
    Neuro Oncology Unit, Daniel den Hoed Cancer Clinic Erasmus University Medical Center, Rotterdam, The Netherlands
    Semin Oncol 31:645-52. 2004
    ..For an improved prognosis, a better understanding of the aberrant pathways and the driving force behind these tumors is required...
  24. pmc Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951
    Mathilde C M Kouwenhoven
    Department of Neurology, Daniel den Hoed Cancer Center, Erasmus University Hospital, Rotterdam, The Netherlands
    Neuro Oncol 11:737-46. 2009
    ..Of all molecular markers analyzed in this study, especially loss of 1p/19q carried prognostic significance, while the others contributed little prognostic value to classical histology...
  25. pmc First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response
    Walter Taal
    Department of Neuro Oncology Neurology, Erasmus MC, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Neuro Oncol 13:235-41. 2011
    ..01) and a methylated MGMT promoter (P = .02). We conclude that MGMT promoter methylation and IDH1 mutations seem to predict survival from the time of diagnosis, but not PFS to TMZ...
  26. doi request reprint A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951
    Martin J van den Bent
    Neuro Oncology Unit, Department of Neurology, Daniel den Hoed Cancer Center Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 17:7148-55. 2011
    ..Subsequent studies indicated that MGMT promoter methylation is a prognostic marker even in patients treated with radiotherapy alone, both in GBMs and in grade III gliomas...
  27. ncbi request reprint 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
    Mathilde C M Kouwenhoven
    Department of Neuro Oncology, Daniel den Hoed Oncology Center, P O Box 5201, 3008AE Rotterdam, The Netherlands
    Eur J Cancer 42:2499-503. 2006
    ..We assessed the impact of 1p and 19q loss on the outcome to first line temozolomide (TMZ) chemotherapy and to second line PCV or TMZ in progressive oligodendroglial tumours...
  28. doi request reprint Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
    Dieta Brandsma
    Department of Neuro Oncology, Daniel den Hoed Cancer Centre, Erasmus Medical Centre, Rotterdam, Netherlands
    Lancet Oncol 9:453-61. 2008
    ..Further research is needed to establish reliable imaging parameters that distinguish between true tumour progression and pseudoprogression or treatment-related necrosis...
  29. ncbi request reprint Intratumoral distribution of 1p loss in oligodendroglial tumors
    Johan M Kros
    Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Neuropathol Exp Neurol 66:1118-23. 2007
    ..918, p < 0.001). These results point to genotypic homogeneity for 1p in oligodendroglial tumors...
  30. pmc MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation
    Floris H Groenendijk
    Department of Pathology, Josephine Nefkens Institute, Be320a, Erasmus MC, University Medical Center Rotterdam, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    J Neurooncol 101:405-17. 2011
    ..These results argue against the putative TP53 G:C>A:T transition mutations suggested to occur preferentially in MGMT hypermethylated tumors...
  31. ncbi request reprint Gene expression profiles associated with treatment response in oligodendrogliomas
    Pim J French
    Department of Neurology, Cancer Genomics Center, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer Res 65:11335-44. 2005
    ..The differentially expressed transcripts can help identify patient subgroups with good prognosis and those that will benefit from chemotherapeutic treatments...
  32. ncbi request reprint Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine
    Elize M Biemond ter Stege
    Department of Neurology Neuro Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 103:802-9. 2005
    ..The authors retrospectively studied the outcome of the procarbazine, lomustine, and vincristine (PCV) chemotherapy regimen in a group of 16 patients with newly diagnosed OD and 5 patients with recurrent low-grade OD...
  33. doi request reprint Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene
    Linda B C Bralten
    Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
    Genes Chromosomes Cancer 49:509-17. 2010
    ..Our data show that integrated genomic profiling can identify genes involved in tumor initiation, and/or progression and can be used as an approach to identify novel fusion genes...
  34. ncbi request reprint Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
    Martin J van den Bent
    Department of Neurooncology, Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 97:1276-84. 2003
    ..The authors investigated the correlation between genetic and clinical characteristics of OD in 33 patients who received chemotherapy with procarbazine, lomustine, and vincristine for recurrent disease after receiving radiotherapy...
  35. pmc Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu
    Lale Erdem-Eraslan
    Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 31:328-36. 2013
    ..Our study includes gene expression profiles of formalin-fixed, paraffin-embedded (FFPE) clinical trial samples...
  36. pmc Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study
    Walter Taal
    Department Neurology Neuro oncology Unit, Erasmus MC University Hospital Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    J Neurooncol 108:195-200. 2012
    ..Our data do not suggest superior efficacy of this schedule as compared to the standard day 1-5 every 4 weeks schedule...
  37. ncbi request reprint Low-molecular weight caldesmon as a potential serum marker for glioma
    Ping Pin Zheng
    Department of Pathology, Erasmus Medical Center, Rotterdam, Netherlands
    Clin Cancer Res 11:4388-92. 2005
    ..Testing the feasibility of using the serum low-molecular weight caldesmon (l-CaD) level as a serum marker for the presence of glioma...
  38. doi request reprint Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
    Walter Taal
    Department of Neuro Oncology Neurology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 113:405-10. 2008
    ..The occurrence of early pseudo-progression was retrospectively assessed in a cohort of malignant glioma patients treated with RT/TMZ...
  39. doi request reprint Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
    Nanne K Kloosterhof
    Department of Neurology and Neuro Oncology, Daniel den Hoed Cancer Center, Netherlands
    Lancet Oncol 12:83-91. 2011
    ..Because IDH1 does not belong to a traditional oncogenic pathway and is specifically and commonly mutated in gliomas, the altered enzymatic activity of IDH1 may provide a fundamentally new understanding of diffuse glioma...
  40. doi request reprint Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study
    Leida M Lamers
    Institute for Medical Technology Assessment bv, Erasmus University Medical Center, Rotterdam, Netherlands
    Cancer 112:1337-44. 2008
    ..The study aimed to compare the cost-effectiveness of concomitant and adjuvant temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma multiforme versus initial radiotherapy alone from a public health care perspective...
  41. ncbi request reprint Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
    M C Y de Wit
    Department of Neuro Oncology Neurology, Daniel den Hoed Cancer Center Erasmus Medical Center, Rotterdam, The Netherlands
    Neurology 63:535-7. 2004
    ..The authors conclude that patients with progressive lesions within 3 months after radiotherapy should not be eligible for phase II trials on recurrent glioma...
  42. ncbi request reprint Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome
    Johan M Kros
    Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Neuropathol Exp Neurol 66:545-51. 2007
    ..The absence of necrosis and the presence of endothelial abnormalities were correlated with better outcomes. In multivariate analysis, patients' age, 1p/19q loss, and necrosis were identified as independent prognostic factors...
  43. ncbi request reprint Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies
    Martin J van den Bent
    Department of Neurology Neuro Oncology Unit, Daniel den Hoed Cancer Center, PO Box 5201, 3008AE, Rotterdam, The Netherlands
    Semin Oncol 30:39-44. 2003
    ..Perhaps then we can answer the question, can chemotherapy replace radiotherapy in low-grade gliomas?..
  44. ncbi request reprint Case-referent comparison of cognitive functions in patients receiving haematopoietic stem-cell transplantation for haematological malignancies: two-year follow-up results
    Helena Harder
    Department of Neuro Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, The Netherlands
    Eur J Cancer 43:2052-9. 2007
    ..Our results suggest limited HSCT-related cognitive dysfunctions. Additional follow-up is necessary to assess long-term effects...
  45. doi request reprint Pseudoprogression and pseudoresponse in the treatment of gliomas
    Dieta Brandsma
    Department of Neuro Oncology, Antoni van Leeuwenhoek Hospital Netherlands Cancer Institute, Amsterdam, The Netherlands
    Curr Opin Neurol 22:633-8. 2009
    ..These criteria depend on changes in the area of enhancement. However, gadolinium enhancement of brain tumours primarily reflects impairment of the blood-brain barrier...
  46. ncbi request reprint Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas
    V H J M Triebels
    Department of Neuro Oncology, Erasmus MC, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Neurology 63:904-6. 2004
    ..Although a clear relation existed between loss of 1p and response to temozolomide chemotherapy, this relation was absent in salvage PCV chemotherapy...
  47. doi request reprint Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis
    Mascha Schuurmans
    Department of Neuro Oncology, Daniel den Hoed Cancer Centre, Erasmus MC, Rotterdam, The Netherlands
    Br J Haematol 151:179-84. 2010
    ..Performance status was the most important variable determining prognosis. Short and long term toxicities must be weighed against possible clinical benefits of each treatment, making treatment decisions a highly individualized process...
  48. ncbi request reprint Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972
    M J van den Bent
    Department of Neuro Oncology, University Hospital Rotterdam Rotterdam Cancer Center, The Netherlands
    Ann Oncol 14:599-602. 2003
    ..We investigated this drug in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after prior PCV chemotherapy and radiation therapy...
  49. doi request reprint Molecular subtypes of glioma identified by genome-wide methylation profiling
    Nanne K Kloosterhof
    Department of Neurology, Erasmus MC, Rotterdam, The Netherlands Department of Pediatric Oncology and Hematology, Sophia, Erasmus MC, Rotterdam, The Netherlands
    Genes Chromosomes Cancer 52:665-74. 2013
    ..Our data demonstrate that methylation profiling identifies at least three prognostically relevant subtypes of glioma that can aid diagnosis and potentially guide treatment for patients. © 2013 Wiley Periodicals, Inc...
  50. doi request reprint Incidence of central nervous system involvement in chronic lymphocytic leukemia and outcome to treatment
    M C J Hanse
    Dept of Neuro Oncology, Daniel den Hoed Cancer Center, 5201, 3008AE Rotterdam, The Netherlands
    J Neurol 255:828-30. 2008
    ..They found an incidence of 1-2% of LI. Most of the patients with LI had a longterm survival, despite failure to clear the cerebrospinal fluid from tumor cells...
  51. ncbi request reprint The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study
    W Boogerd
    Department of Neuro Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 40:2726-33. 2004
    ..Addition of intraventricular chemotherapy does not lead to survival benefit or improved neurological response, and is associated with an increased risk of neurotoxicity...
  52. ncbi request reprint Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas
    Erkan Kurt
    Department of Neurosurgery, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer 106:388-95. 2006
    ..Furthermore, in many investigations, myxopapillary ependymomas and subependymomas were included and may have confounded results, because those tumors should be considered clinicopathologic entities distinct from the other ependymomas...
  53. doi request reprint Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology
    Lonneke A M Gravendeel
    Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Cancer Res 69:9065-72. 2009
    ..Molecular classification therefore may aid diagnosis and can guide clinical decision making...
  54. ncbi request reprint [Three patients with a paraneoplastic neurological syndrome: the significance of paraneoplastic antibodies]
    P A E Sillevis Smitt
    Ned Tijdschr Geneeskd 151:874-80. 2007
    ..During chemotherapy for a non seminoma testicular cancer, the limbic encephalitis improved both clinically and radiologically, but the patient died as a result of the toxicity of the treatment...
  55. doi request reprint IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
    H J Dubbink
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Neurology 73:1792-5. 2009
    ....
  56. ncbi request reprint Cognitive status and quality of life after treatment for primary CNS lymphoma
    H Harder
    Department of Neuro Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Neurology 62:544-7. 2004
    ..All patients were in complete remission after combined modality treatment with IV and intrathecal high-dose methotrexate (MTX)-based chemotherapy followed by whole brain radiotherapy (WBRT)...
  57. ncbi request reprint [Favourable result for temozolomide in recurrent high-grade glioma]
    W Taal
    Erasmus MC, locatie Daniel den Hoed Oncologisch Centrum, Postbus 5201, Rotterdam
    Ned Tijdschr Geneeskd 149:1393-9. 2005
    ..To describe the results of the treatment of recurrent glioma with temozolomide...
  58. ncbi request reprint Temozolomide chemotherapy in recurrent oligodendroglioma
    M J van den Bent
    Department of Neuro Oncology, University Hospital Rotterdam Rotterdam Cancer Center, The Netherlands
    Neurology 57:340-2. 2001
    ..Median time to progression in responding patients was 13 months. Temozolomide shows promise and has an acceptable safety profile in recurrent anaplastic oligodendroglial tumors. Patients not responding to PCV may respond to temozolomide...
  59. ncbi request reprint CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies
    J E C Bromberg
    Department of Neuro Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Neurology 68:1674-9. 2007
    ....
  60. ncbi request reprint Neurocognitive functions and quality of life in haematological patients receiving haematopoietic stem cell grafts: a one-year follow-up pilot study
    Helena Harder
    Department of Neuro Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Exp Neuropsychol 28:283-93. 2006
    ..These preliminary results emphasize the significance of a pre-treatment assessment and the need of a large baseline sample in future longitudinal studies to overcome the expected dropout rate of more than 50%...
  61. pmc End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria
    Martin J van den Bent
    Neuro Oncology Unit, Daniel den Hoed Cancer Center, Erasmus University Hospital, Rotterdam, The Netherlands
    J Clin Oncol 27:2905-8. 2009
    ..This requires a critical and comprehensive review of how brain tumor trials are conducted, particularly of which end points are defined and how response and progression are defined...
  62. ncbi request reprint Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors
    Ping Pin Zheng
    Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    J Neuropathol Exp Neurol 62:855-62. 2003
    ..It is concluded that the combination of 2D PAGE and MALDI-TOF-MS is successful as an unbiased global screening tool for CSF...
  63. ncbi request reprint Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity
    Floris A de Jong
    Department of Medical Oncology, Erasmus MC University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Biol Ther 6:1368-74. 2007
    ..Here, we report on the pharmacokinetic and pharmacodynamic effects of this combination in a cancer patient...
  64. ncbi request reprint The diagnosis and management of brain metastases
    M J van den Bent
    Department of Neuro Oncology, Rotterdam Cancer Centre, University Hospital Rotterdam, PO Box 5201, 3008AE Rotterdam, The Netherlands
    Curr Opin Neurol 14:717-23. 2001
    ..New randomized trials are needed, however, to investigate this further. The response rate of brain metastases to chemotherapy is similar to the response rate of the primary tumour and non-cerebral metastases...
  65. doi request reprint Oligodendrogliomas: molecular biology and treatment
    Jacolien E C Bromberg
    Neuro Oncology Unit, Daniel den Hoed Cancer Center Erasmus University Medical Center, Rotterdam, The Netherlands
    Oncologist 14:155-63. 2009
    ..The molecular explanation for the greater sensitivity of 1p/19q codeleted tumors is still unclear, and this could, in part, be explained by more frequent MGMT promoter gene methylation...
  66. ncbi request reprint Resolution of EBV(+) CNS lymphoma with appearance of CSF EBV-specific T cells
    Janet W de Beukelaar
    Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Ann Neurol 58:788-92. 2005
    ..The appearance of EBV-specific CD8(+) T cells in CSF and blood correlated with neurological improvement and disappearance of EBV-LPD. These observations suggest a role for EBV-specific CD8(+) T cells in the control of EBV-LPD in the CNS...
  67. ncbi request reprint Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma
    M J van den Bent
    Department of Neuro Oncology, Daniel den Hoed Cancer Clinic and University Hospital Rotterdam, The Netherlands
    J Neurooncol 44:59-64. 1999
    ..Because relatively good results have been achieved with combinations of platin compounds and etoposide, we investigated a dose-intensified cisplatin regimen with oral etoposide...
  68. pmc Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin
    P H Hilkens
    Department of Neuro Oncology, Dr Daniel den Hoed Cancer Center and University Hospital, Rotterdam, The Netherlands
    Br J Cancer 75:417-22. 1997
    ..01) as well as the post-treatment VPT (P < 0.01). The neurotoxic effects of this combination were more severe than either cisplatin or docetaxel as single agent at similar doses...
  69. ncbi request reprint New perspectives for the diagnosis and treatment of oligodendroglioma
    M J van den Bent
    Department of Neuro Oncology, Dr Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, The Netherlands
    Expert Rev Anticancer Ther 1:348-56. 2001
    ..Temozolomide appears to be a promising drug in OD...
  70. ncbi request reprint Adjuvant treatment of high grade gliomas
    M J van den Bent
    Department of Neuro Oncology, Erasmus University Hospital Rotterdam Rotterdam Cancer Center, Rotterdam, The Netherlands
    Ann Oncol 17:x186-90. 2006
  71. ncbi request reprint Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies
    M J van den Bent
    Department of Neuro Oncology, University Hospital and Daniel den Hoed Cancer Center, P O Box 5201, 3008 AE Rotterdam, Netherlands
    Ann Hematol 81:187-91. 2002
    ..Normal sCD27 concentrations in CSF samples of patients with chronic lymphoproliferation makes LI unlikely, but the determination of CSF sCD27 is not sufficiently specific to serve as a reliable tumor marker...
  72. ncbi request reprint Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer
    F E de Jongh
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, PO Box 5201, The Netherlands
    Eur J Cancer 38:2005-13. 2002
    ..In conclusion, both cisplatin/paclitaxel regimens showed excellent activity with manageable toxicity in patients with advanced ovarian cancer...
  73. ncbi request reprint Assessment of pre-treatment cognitive performance in adult bone marrow or haematopoietic stem cell transplantation patients: a comparative study
    Helena Harder
    Department of Neuro Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, The Netherlands
    Eur J Cancer 41:1007-16. 2005
    ..This study showed impaired cognitive performance prior to SCT. Haematological patients treated with non-myeloablative cancer therapies proved to be a reliable reference group for longitudinal studies...
  74. ncbi request reprint Diagnosis of neurolymphomatosis with FDG PET
    Sonja M Rosso
    Departments of Neurology Neuro Oncology, Daniel den Hoed Cancer Center Erasmus University Hospital, Rotterdam, The Netherlands
    Neurology 67:722-3. 2006
  75. ncbi request reprint EORTC Brain Tumor Group: achievements and perspectives
    Ch J Vecht
    Neuro Oncology Unit, Department of Neurology, Medical Center Haaglanden Westeinde, POB 432, 2501 CK, The Hague, The Netherlands
    Eur J Cancer 38:S35-8. 2002
    ..The number of centres and patients joining its trials have greatly increased over the past 2 years. Achievements and strategies are detailed in this article...
  76. ncbi request reprint Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity
    M J van den Bent
    Department of Neuro Oncology, Daniel den Hoed Cancer Clinic University Hospital Rotterdam, PO Box 5201, 3008 AE, Rotterdam, The Netherlands
    Eur J Cancer 38:387-91. 2002
    ....
  77. ncbi request reprint Glial fibrillary acidic protein and its fragments discriminate astrocytoma from oligodendroglioma
    T M Luider
    Dept of Neuro Oncology, Daniel den Hoed Cancer Center, University Hospital Rotterdam Dijkzigt, Rotterdam, The Netherlands
    Electrophoresis 20:1087-91. 1999
    ..It is concluded that 2-DE and 1-DE GFAP immunoblotting provide accurate information for the reliable discrimination of anaplastic astrocytomas and oligodendrogliomas...
  78. ncbi request reprint Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation
    Helena Harder
    Department of Neuro Oncology, University Hospital Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 95:183-92. 2002
    ..The late neurotoxic effects of bone marrow transplantation (BMT) on cognitive functioning and quality of life (QOL) were investigated in a consecutively treated cohort of long-term adult survivors...
  79. pmc Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients
    F E de Jongh
    Department of Medical Oncology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Br J Cancer 88:1199-206. 2003
    ..Symptomatic hearing loss occurred in 15% with anaemia as the predisposing factor. We conclude that weekly high-dose cisplatin administered in hypertonic saline is a feasible treatment regimen...
  80. ncbi request reprint Cisplatin-induced encephalopathy and seizures
    N Steeghs
    Department of Medical Oncology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Anticancer Drugs 14:443-6. 2003
    ..One patient was rechallenged with cisplatin after which he developed a second episode of encephalopathy. We conclude that physicians using cisplatin chemotherapy should be aware of this rare complication...
  81. ncbi request reprint Negative sural nerve biopsy in neurolymphomatosis
    M J van den Bent
    Department of Neuro Oncology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Neurol 246:1159-63. 1999
    ..Some patients with neurolyphomatosis have only focal or proximal involvement of nerves, requiring the biopsy of an affected part of these nerves. Magnetic resonance imaging may be useful in identifying affected nerves...
  82. doi request reprint Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)
    Jerzy Hildebrand
    Hopital Universitaire Erasme, Brussels, Belgium
    Eur J Cancer 44:1210-6. 2008
    ..The aim of the present study was to test this adjuvant regimen in a larger number of AA patients...
  83. ncbi request reprint Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial
    René Olivier Mirimanoff
    Department of Radiation Oncology, University Hospital Lausanne, Lausanne, Switzerland
    J Clin Oncol 24:2563-9. 2006
    ..We evaluated in this trial whether the recursive partitioning analysis (RPA) retains its overall prognostic value and what the benefit of the combined modality is in each RPA class...
  84. ncbi request reprint Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study
    Murielle E L Mauer
    European Organisation for Research and Treatment of Cancer Data Center, Quality of Life Unit, Ave Mounier 83 11, Brussels, Belgium 1200
    J Clin Oncol 25:5731-7. 2007
    ..This is one of a few studies that have explored the value of baseline symptoms and health-related quality of life (HRQOL) in predicting survival in patients with brain cancer...
  85. ncbi request reprint Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial
    Martin J B Taphoorn
    Department of Neurology, Medical Center Haaglanden Westeinde Ziekenhuis, The Hague, The Netherlands
    J Clin Oncol 25:5723-30. 2007
    ....
  86. ncbi request reprint Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
    Thierry Gorlia
    EORTC Data Centre, Brussels, Belgium
    Lancet Oncol 9:29-38. 2008
    ....
  87. ncbi request reprint Molecular targeted therapies and chemotherapy in malignant gliomas
    Dieta Brandsma
    Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands
    Curr Opin Oncol 19:598-605. 2007
    ..To review current developments in the field of chemotherapy and targeted treatment of high-grade glioma...
  88. ncbi request reprint Changing paradigms--an update on the multidisciplinary management of malignant glioma
    Roger Stupp
    Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 Rue du Bugnon, Lausanne 1011, Switzerland
    Oncologist 11:165-80. 2006
    ..This review summarizes recent developments, focusing on the clinical management of patients in daily neuro-oncology practice...
  89. ncbi request reprint Health-related quality of life in patients with glioblastoma: a randomised controlled trial
    Martin J B Taphoorn
    Medical Centre Haaglanden, The Hague, The Netherlands
    Lancet Oncol 6:937-44. 2005
    ..This paper reports the health-related quality of life (HRQOL) of the patients in this trial...
  90. ncbi request reprint Optimal role of temozolomide in the treatment of malignant gliomas
    Roger Stupp
    Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 Rue du Bugnon, Lausanne 1011, Switzerland
    Curr Neurol Neurosci Rep 5:198-206. 2005
    ..This review summarizes the current knowledge, highlights approved and nonapproved indications, and describes molecular studies that may allow us to identify the patients most likely to benefit from this treatment...
  91. ncbi request reprint Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    Roger Stupp
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    N Engl J Med 352:987-96. 2005
    ..In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety...
  92. pmc Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
    Eric Raymond
    Service inter hospitalier de cancérologie, Beaujon University Hospital, Clichy
    J Clin Oncol 26:4659-65. 2008
    ..To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas...
  93. ncbi request reprint Intracranial granulocytic sarcoma (chloroma) may mimic a subdural hematoma
    Martijn H Smidt
    J Neurol 252:498-9. 2005